2012 was good, but not great, for biotech VC

01/31/2013 | Forbes

Upfront deal values for venture capital-backed biotech mergers and acquisitions totaled about $3.5 billion last year, which is lower than in 2011 but better than 2008 to 2010, according to data from HBM Partners. Total annual VC-backed private acquisitions have held steady since 2005. The time period from founding to trade sale appears to have risen from about five years in 2005 to nine years in 2012, notes Atlas Venture partner Bruce Booth.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN